drugset / Trial / NCT01611363

A Phase 1 Study to Investigate the Mechanism of Action of Ipragliflozin

NCT01611363

Phase 1 Completed 44 enrolled Astellas Pharma Europe B.V.
RandomizedCrossoverQuadruple-blindBasic science

Summary

In this study the effect of ipragliflozin on glucose homeostasis in healthy subjects and T2DM subjects, and the effect of exposure of ipragliflozin on urinary glucose excretion and plasma glucose in T2DM subjects will be investigated.

Timeline

Start
2011-10-27
Primary completion
2012-02-03
Completion
2012-02-03

Drugs

EvaluationDrugModalityDoseRoute
Subject ipragliflozin Small molecule Oral